Insider Trading & Ownership of David E. Lazar

Location
Panama City
Summary
The estimated net worth of David E. Lazar is at least $48,637,612 dollars as of 02 Apr 2026. David E. Lazar is the 10%+ Owner of NovaBay Pharmaceuticals, Inc. and owns shares of NovaBay Pharmaceuticals, Inc. (NBY) stock worth about $36.03M. David E. Lazar is the Director, 10%+ Owner of MINIM, INC. and owns shares of FiEE, Inc. (FIEE) stock worth about $7.28M. David E. Lazar is the Director of Sow Good Inc. and owns shares of Sow Good Inc. (SOWG) stock worth about $4.98M. David E. Lazar is the Chief Executive Officer, Director of TITAN PHARMACEUTICALS INC and owns shares of TITAN PHARMACEUTICALS INC (TTNP) stock worth about $123K. David E. Lazar is the President, Director of LQR House Inc. and owns shares of LQR House Inc. (YHC) stock worth about $99K. David E. Lazar is the Chief Executive Officer, Director, 10%+ Owner of OPGEN INC and owns shares of CapForce Inc. (OPGN) stock worth about $85K. David E. Lazar is the 10%+ Owner of Cyclacel Pharmaceuticals, Inc. and owns shares of Bio Green Med Solution, Inc. (BGMS) stock worth about $49.9K.
Signature
/s/ David Lazar
All Insider Reports
All Insider Reports

Notify me when David E. Lazar files a new Insider Trading report.

⭐ Subscribe ⭐

Sponsored

Ownership of David E. Lazar

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
NBY NovaBay Pharmaceuticals, Inc. 10%+ Owner $36,028,320 21 Oct 2025
FIEE MINIM, INC. Director, 10%+ Owner $7,277,290 18 Feb 2025
SOWG Sow Good Inc. Director $4,975,134 31 Mar 2026
TTNP TITAN PHARMACEUTICALS INC Chief Executive Officer, Director $123,000 26 Jul 2023
YHC LQR House Inc. President, Director $99,000 02 Apr 2025
OPGN OPGEN INC Chief Executive Officer, Director, 10%+ Owner $85,000 30 Jul 2024
BGMS, BGMSP Cyclacel Pharmaceuticals, Inc. 10%+ Owner $49,868 30 Jul 2025
INDP Indaptus Therapeutics, Inc. Director $0 23 Mar 2026
KALA KALA BIO, Inc. Chief Executive Officer, Director $0 18 Dec 2025
MYNZ MAINZ BIOMED N.V. Director $0 13 Feb 2026
TCON Tracon Pharmaceuticals, Inc. Chief Business Dev Officer 07 May 2024

Insider Transactions Reported by David E. Lazar:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.